The University of Chicago Header Logo

Connection

Mark J. Ratain to Receptors, Interleukin-2

This is a "connection" page, showing publications Mark J. Ratain has written about Receptors, Interleukin-2.
Connection Strength

0.120
  1. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998 Jan 15; 91(2):399-405.
    View in: PubMed
    Score: 0.040
  2. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer. 1997 Jan; 33 Suppl 1:S34-6.
    View in: PubMed
    Score: 0.037
  3. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood. 1990 Nov 15; 76(10):1941-5.
    View in: PubMed
    Score: 0.024
  4. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998 Jul; 39(1):63-73.
    View in: PubMed
    Score: 0.010
  5. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.